Novartis India Limited (NOVARTIND) fundamentals
Novartis India Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as NOVARTIND (ISIN INE234A01025). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Novartis India Limited does
Novartis India Limited is an India-based company. The Company is primarily engaged in the business of trading of Pharmaceuticals. It operates in the Pharmaceutical business segment. The Company’s brands hold key positions in therapeutic areas, such as, Voveran, which is the brand for bone and pain; Simulect, Certican, Sandimmun, Neoral, and Myfortic, which is the brand for transplantation immunology; and Tegrital and Exelon, which is the brand for neurosciences.
Valuation and market data
| Last close | ₹2391.30 |
|---|---|
| Market capitalisation | ₹5,904 crore |
| Enterprise value | ₹5,872 crore |
| P/E (TTM) | 0.00 |
| Price to book | 7.52 |
| Price to sales (TTM) | 14.49 |
| Book value per share | ₹317.95 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Apr 20 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹393 crore | ₹130 crore | ₹93 crore | 0.00 |
| Mar 2025 | ₹398 crore | ₹130 crore | ₹101 crore | 40.87 |
| Mar 2024 | ₹397 crore | ₹123 crore | ₹85 crore | 34.50 |
| Mar 2023 | ₹437 crore | ₹115 crore | ₹103 crore | 41.86 |
| Mar 2022 | ₹433 crore | ₹-4 crore | ₹-4 crore | -1.51 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jul 2026:
| Promoters | 70.7% |
|---|---|
| Foreign institutions (FII) | 0.1% |
| Mutual funds | 0.7% |
| Other domestic institutions | 0.7% |
| Retail and others | 27.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.